MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • MDS Virtual Congress 2021

    Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.

    N. France, C. Tomkins-Lane, M. Maurer, C. Barlow, E. Davies, C. Matthews, A. Palozoglu, L. Farid (South San Francisco, USA)

    Objective: To identify candidate wearable devices or digital solutions suitable for conducting the Timed Up and Go (TUG) test and evaluate real-world performance remotely during…
  • MDS Virtual Congress 2021

    LRRK2 Inhibition by BIIB122 / DNL151: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Ph 1 Healthy Volunteer and Ph 1B Parkinson’s Disease Trials

    D. Jennings, J. Wetering Derooij, M. Vissers, J. Heuberger, G. Groeneveld, R. Macuica, A. Kay, M. Borin, B. Wong, V. Daryani, S. Huntwork-Rodriguez, P. Chin, C. Ho, M. Troyer (South San Francisco, USA)

    Objective: To evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of the LRRK2 inhibitor, DNL151 (BIIB122), in healthy volunteers (HVs) and Parkinson’s disease (PD) patients. Background:…
  • MDS Virtual Congress 2021

    Defining LRRK2-PD subsets based on olfactory function in the PPMI

    K. Marek, A. Siderowf, C. Tanner, T. Simuni, L. Chahine, M. Brumm, C. Coffey (New Haven, USA)

    Objective: A major goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical and biomarker defined disease subsets that may demonstrate differing disease…
  • MDS Virtual Congress 2020

    Virtual Assessment of LRRK2 Carriers to Optimize Research in Parkinson Disease (VALOR-PD): A Comparison to Traditional Cohorts

    S. Jensen-Roberts, T. Myers, K. Amodeo, S. Sharma, R. Alcalay, E. Dorsey, R. Holloway, R. Schneider (Rochester, NY, USA)

    Objective: To compare a national virtual cohort of LRRK2 G2019S carriers, identified via a personal genetics company, to existing traditional cohorts. Background: Advancements in personal…
  • MDS Virtual Congress 2020

    Rare variants of the LRRK2 gene in the haplotype as one of the potential risk factors for endemic parkinsonism in a small isolated region in the Czech Republic

    P. Kaňovský, K. Kolaříková, R. Vodička, R. Vrtěl, K. Menšíková, T. Bartoníková, M. Procházka (Olomouc, Czech Republic)

    Objective: The aim of the study was to investigate a co-occurence of rare variants in set of genes frequently associated with parkinsonism. Background: The increased…
  • MDS Virtual Congress 2020

    Interest of multiplex ligation-dependent probe amplification assay to identify pathogenic mutations in Parkinson’s disease patients

    E. Mutez, M. Swiderski, L. Defebvre, M.C Chartier-Harlin, V. Huin (Lille, France)

    Objective: To evaluate the interest of the MLPA (Multiplex Ligation-dependent Probe Amplification) commercially available kit in the genetic testing in Parkinson’s disease (PD). Background: PD…
  • MDS Virtual Congress 2020

    LRRK2 p.G2019S and p.N2081D variants as modifiers of glucocerebrosidase activity

    K. Senkevich, E. Yu, L. Krohn, U. Rudakou, J. Ruskey, F. Asayesh, K. Mufti, S. Laurent, D. Spiegelman, S. Fahn, C. Waters, P. Sardi, G. Rouleau, R. Alcalay, Z. Gan-Or (Montreal, QC, Canada)

    Objective: To examine whether the activity of the lysosomal enzyme glucocerebrosidase (GCase) is associated with LRRK2 variants. Background: Mutations in GBA (which encodes GCase) and…
  • MDS Virtual Congress 2020

    LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression

    T. Usnich, N. Schell, E.J Vollstedt, V. Skrahina, X. Bogdanovic, N. Koleva-Alazeh, I. Csoti, T. Förster, A. Heuer, N. Brüggemann, P. Bauer, M. Kasten, A. Rolfs, C. Klein (Luebeck, Germany)

    Objective: The international multicenter LIPAD study is a deep-phenotyping, follow-up study to ROPAD (Rostock Parkinson’s Disease Study) with the aim to systematically characterize Parkinson's disease…
  • MDS Virtual Congress 2020

    Characterizing Global Cohorts with Monogenic Parkinson’s Disease

    E.J Vollstedt, S. Schaake, M. Kasten, K. Lohmann, C. Klein (Lübeck, Germany)

    Objective: To clinically and genetically characterize a global sample of subjects with monogenic Parkinson’s disease (mPD) and unaffected mutation carriers. Background: Publications on patients with…
  • MDS Virtual Congress 2020

    The role of peripheral T- and B-lymphocytes in LRRK2-mediated Parkinson’s disease

    E. Kozina, M. Byrne, L. Oakley, R. Smeyne (Philadelphia, PA, USA)

    Objective: To test the hypothesis the neurodegenerative cascade in the CNS that leads to Parkinson’s disease (PD) is initiated by signals emanating from the peripheral…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • #23812 (not found)
  • Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time
  • Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley